Immunotherapy including ICIs targeting PD-1/PD-L1 and CTLA-4 in HNSCC has shown as potential therapeutics in HNSCC, while TIME affects the responsiveness and resistance of treatment. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.